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WHERE IS BIOTECHNOLOGY GOING?
Extracte de la conferencia impartida pel Professor Julian E. D.AVIES de 17nstitut Pasteur a
Paris , Franca, durant la celebracio del 2n. Congres Espanyol de Biotecnologia (BIOTEC-88) a
Barcelona , el dia 22 de juny de 1988.
It has been my privilege to spend fifteen
exciting years working in modern biotechno-
logy. Biotechnology has, in fact , contrib-
uted to man's health and well -being for
more than ten thousand years. However,
biotechnology can be clearly divided into
two distinct phases : before 1973, and after
1973, which is to say before and after Co-
HEN and BoYER. Before 1973 biotechno-
logy was essentially an art: you took an
organism and you took what that organism
could do for you. All manipulations of in-
dustrial processes in biotechnology were
largely determined by the properties of the
organism being used. After 1973 biotechno-
logy became a real science. The disco-
very of recombinant DNA, and the deve-
lopment of genetic engineering technology
brought about a revolution; organisms
could be tailored at will. If someone had
said in 1970 that Escherichia coli K12
would be an industrial microorganism,
people would have laughed at this idea. If
the same person had said that, in addition,
mammalian cells, and insect cells would be
used extensively in industry, this person
would have been locked up in an insane
asylum!
However, these are the new industrial
microorganisms. Another very important
change in biotechnology which occurred
after 1973 was the development of entre-
preneurship. This incredible race to de-
velop commercial products from recombi-
nant DNA played a crucial role in the
rapid growth of the new science. Small
biotechnology companies with their acade-
mic-industry combination accelerated dis-
covery, and have been making highly sig-
nificant contributions. Companies like Ge-
nentech (whose scientists published more
than two hundred papers in 1987) may
have been formed to make money, but
their scientific contributions have been
awesome.
Something else has happened since
1973. Not only has the application of re-
combinant DNA produced many new and
important medical products such as hu-
man insulin , human interferon , and hu-
man growth hormone, but biotechnology
has developed into a subject; it has evol-
ved into a new science in its own right.
Biotechnology is not routine. It is some-
thing more than the cloning of proteins in E.
coli. Everything that could be cloned (from
knowledge of its existence and properties)
has been cloned. This has led scientists
into developing the field into the true
realm of science: the discovery and analy-
sis of new biological phenomena.
Murray GELL-MANN, Nobel Prize win-
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ner in physics, talked about modern scien-
ce in the following way.
"New subjects, highly interdisciplinary in
traditional terms, are emerging, and repre-
sent in many cases the frontiers of research.
These interdisciplinary areas do not link
together the whole of one traditional disci-
pline with another: particular sub-fields are
joined together to snake a new subject. "
We saw this first in the development of
molecular biology, but in my opinion this
is no case more true than with biotechno-
logy. It is in this context that I see the real
future of the science of biotechnology: a
new fusion of traditional sub-fields provid-
ing new ways of both analysing biological
phenomena and developing these funda-
mental discoveries to improve the human
condition.
Let me give you a few examples of this
type of fusion. If we consider the now
commonplace procedure of cloning and se-
cretion of a heterologous protein, we can
see how this implicates knowledge and ap-
plication of a variety of sub-fields such as
cell physiology and genetics, membrane
structure, secretion mechanisms, gene ex-
pression, enzymology, protein structure,
computing and chemical engineering.
A more recent example concerns the de-
velopment of the polymerase chain reac-
tion PCR, which is surely going to be one
of the most significant advances in the
field. The technology will revolutionise sev-
eral fields: clinical diagnosis, crime detec-
tion (identifying a person by the analysis
of a single hair!), basic cloning methodo-
logy, to name just a few of them. The PCR
system would not have been developed
without a successful marriage of specific
aspects of fields such as enzymology, nu-
cleic acid chemistry, synthetic organic che-
mistry. physical chemistry, engineering
and computing.
When considering the future of biotech-
nology it is worthwhile remembering that
our major concern will be with interactions
between biological systems: many of these
interactions are already under intensive
study and new information is rapidly forth-
coming.
It is easy to see how sub-field specialities
are being used to analyse these interactions
and to provide tools and products; for
example, the growth of receptor biology.
In this particular case, the role of traditio-
nal gene cloning is simply one of isolation
and availability; the pharmaceutical pro-
ducts of the future will come from the
study of receptor/ligand interactions, the
receptors having been identified and iso-
lated by techniques which are already well
established. In this example, we are not
simply considering receptors for proteins
such as hormones, but studying receptors
for smell, taste, touch by the interactive
approaches provided by biotechnology. As
the methodology develops (e.g. PCR) we
will be able to analyse these relationships
with increasing sensitivity and accuracy.
It is all too easy to say that biotechno-
logy has not succeeded in all its attempted
applications. This is nowhere more true
than in the development of vaccines. Dur-
ing the birth of modern biotechnology,
everyone proposed that new, safe, stable
vaccines to most diseases would be the
easiest and fastest product. And were are
we? The major product is a vaccine against
hepatitis B, made in Saccharomvices cereri-
siae. It should be pointed out that this
major new vaccine product took only eight
years from cloning to market. This can be
considered to be a success. Even in the
so-called failures, we can look at what we
have learned. For example, even though
not many vaccines have succeeded, what
seemed to be "failures" have led to rapid,
new diagnostic techniques. Biotechnology
has brought indeed a deeper understand-
ing.
I have concentrated on human health
aspects of biotechnology, but we must not
forget that many other applications will
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reach fruition in the future: biomass con-
version, energy production, fine chemical
production, and a whole host of applica-
tions in agriculture, such as herbicide and
disease resistant plants, transgenics.
Finally, even though it must be evident
that I am very enthusiastic and optimistic
about the future of biotechnology, before
concluding I would like to express two
concerns I have.
The first is with respect to regulation. In
the late 70's and early 80's there was much
quasi-political activity relative to genetic
engineering. Fortunately good sense and
reason prevailed, but we are now facing
new problems with «luddisin». These will
undoubtedly be satisfied by an intelligent
approach involving free information flow
and education. However, the danger is that
it may be necessary to dissipate too much
energy and funds on things that might go
wrong. Of course all aspects of the control-
led release of genetically-engineered orga-
nisms must be considered and studied in
detail, but it must be realised that we can
only, at the end, use these new products
with the reasonable prediction that based
on research, there is no finite harm factor.
Unfortunately the press can always devise
science fiction scenarios!
Another and more serious concern is the
future progress of biotechnology. Because
of the entrepreneurship and excitement in
the development of the field, it is apparent
that potential new products and applica-
tions are arriving at a faster rate than they
can be developed commercially. I would
like to see the entrepreneurship of the
science being matched by entrepreneur-
ship in government and industry. The fu-
ture of biotechnology is not limited by our
imagination, but only by support -moral,
financial and commercial. Only in coun-
tries where industry and government pro-
vide this kind of support will the real bene-
fits of biotechnology be made available to
the population. The others will, by defini-
tion, become dependent. I am pleased that
the European Community is trying to ap-
proach this problem, but even here bu-
reaucracy, slow decisions and lack of funds
will limit our benefits unless steps are ta-
ken to put entrepreneurship in govern-
ment as well.
